|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar
|
|
2
|
Siewert JR, Böttcher K, Stein HJ and Roder
JD: Relevant prognostic factors in gastric cancer: ten-year results
of the German Gastric Cancer Study. Ann Surg. 228:449–461.
1998.PubMed/NCBI
|
|
3
|
Hartgrink HH and van de Velde CJ: Status
of extended lymph node dissection: locoregional control is the only
way to survive gastric cancer. J Surg Oncol. 90:153–165. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
McCulloch P, Niita ME, Kazi H and
Gama-Rodrigues JJ: Gastrectomy with extended lymphadenectomy for
primary treatment of gastric cancer. Br J Surg. 92:5–13. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
De Vita F, Vecchione L, Galizia G, et al:
Perspectives in adjuvant therapy of gastric cancer. Oncology.
77(Suppl 1): 38–42. 2009.PubMed/NCBI
|
|
6
|
Macdonald JS, Smalley SR, Benedetti J, et
al: Chemoradiotherapy after surgery compared with surgery alone for
adenocarcinoma of the stomach or gastroesophageal junction. N Engl
J Med. 345:725–730. 2001. View Article : Google Scholar
|
|
7
|
Cunningham D, Allum WH, Stenning SP, et
al: Perioperative chemotherapy versus surgery alone for resectable
gastroesophageal cancer. N Engl J Med. 355:11–20. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Yoong J, Michael M and Leong T: Targeted
therapies for gastric cancer: current status. Drugs. 71:1367–1384.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Meza-Junco J and Sawyer MB: Metastatic
gastric cancer - focus on targeted therapies. Biologics. 6:137–146.
2012.PubMed/NCBI
|
|
10
|
Vollmers HP, O’Connor R, Müller J,
Kirchner T and Müller-Hermelink HK: SC-1, a functional human
monoclonal antibody against autologous stomach carcinoma cells.
Cancer Res. 49:2471–2476. 1989.PubMed/NCBI
|
|
11
|
Hensel F, Hermann R, Schubert C, et al:
Characterization of glycosylphosphatidylinositol-linked molecule
CD55/decay-accelerating factor as the receptor for antibody
SC-1-induced apoptosis. Cancer Res. 59:5299–5306. 1999.PubMed/NCBI
|
|
12
|
Vollmers HP, Dämmrich J, Hensel F, et al:
Differential expression of apoptosis receptors on diffuse and
intestinal type stomach carcinoma. Cancer. 79:433–440. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Fornaro L, Lucchesi M, Caparello C, et al:
Anti-HER agents in gastric cancer: from bench to bedside. Nat Rev
Gastroenterol Hepatol. 8:369–383. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Vollmers HP, Dämmrich J, Ribbert H,
Wozniak E and Müller-Hermelink HK: Apoptosis of stomach carcinoma
cells induced by a human monoclonal antibody. Cancer. 76:550–558.
1995. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Vollmers HP, Hensel F, Hermann R, et al:
Tumor-specific apoptosis induced by the human monoclonal antibody
SC-1: A new therapeutical approach for stomach cancer. Oncol Rep.
5:35–40. 1998.PubMed/NCBI
|
|
16
|
Illert B, Otto C, Vollmers HP, Hensel F,
Thiede A and Timmermann W: Human antibody SC-1 reduces disseminated
tumor cells in nude mice with human gastric cancer. Oncol Rep.
13:765–770. 2005.PubMed/NCBI
|
|
17
|
Illert B, Fein M, Otto C, et al:
Disseminated tumor cells in the blood of patients with gastric
cancer are an independent predictive marker of poor prognosis.
Scand J Gastroenterol. 40:843–849. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Vollmers HP, Zimmermann U, Krenn V, et al:
Adjuvant therapy for gastric adenocarcinoma with the
apoptosis-inducing human monoclonal antibody SC-1: First clinical
and histopathological results. Oncol Rep. 5:549–552.
1998.PubMed/NCBI
|
|
19
|
Becker K, Langer R, Reim D, et al:
Significance of histopathological tumor regression after
neoadjuvant chemotherapy in gastric adenocarcinomas: a summary of
480 cases. Ann Surg. 253:934–939. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Shah MA, Ramanathan RK, Ilson DH, et al:
Multicenter phase II study of irinotecan, cisplatin, and
bevacizumab in patients with metastatic gastric or gastroesophageal
junction adenocarcinoma. J Clin Oncol. 24:5201–5206. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Beutner U, Lorenz U, Illert B, et al:
Neoadjuvant therapy of gastric cancer with the human monoclonal IgM
antibody SC-1: Impact on the immune system. Oncol Rep. 19:761–769.
2008.PubMed/NCBI
|
|
22
|
Smalley SR, Benedetti JK, Haller DG, et
al: Updated analysis of SWOG-directed intergroup study 0116: a
phase III trial of adjuvant radiochemotherapy versus observation
after curative gastric cancer resection. J Clin Oncol.
30:2327–2333. 2012. View Article : Google Scholar
|
|
23
|
Heiss MM, Simon EH, Beyer BC, et al:
Minimal residual disease in gastric cancer: evidence of an
independent prognostic relevance of urokinase receptor expression
by disseminated tumor cells in the bone marrow. J Clin Oncol.
20:2005–2016. 2002. View Article : Google Scholar
|
|
24
|
Braun S, Vogl FD, Naume B, et al: A pooled
analysis of bone marrow micrometastasis in breast cancer. N Engl J
Med. 353:793–802. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Allard WJ, Matera J, Miller MC, et al:
Tumor cells circulate in the peripheral blood of all major
carcinomas but not in healthy subjects or patients with
nonmalignant diseases. Clin Cancer Res. 10:6897–6904. 2004.
View Article : Google Scholar
|
|
26
|
Braun S, Pantel K, Müller P, et al:
Cytokeratin-positive cells in the bone marrow and survival of
patients with stage I, II, or III breast cancer. N Engl J Med.
342:525–533. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Illert B, Otto C, Braendlein S, Thiede A
and Timmermann W: Optimization of a metastasizing human gastric
cancer model in nude mice. Microsurgery. 23:508–512. 2003.
View Article : Google Scholar : PubMed/NCBI
|
